aTyr Pharma (NASDAQ:ATYR) Rating Lowered to Neutral at Cantor Fitzgerald

aTyr Pharma (NASDAQ:ATYR – Get Free Report) was downgraded by research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a report issued on Monday, MarketBeat reports. Several other analysts have also issued reports on the company. Wells Fargo & Company upped their price objective on aTyr Pharma from $17.00 to […]

Leave a Reply

Your email address will not be published.

Previous post Canaccord Genuity Group Reiterates “Hold” Rating for FuelCell Energy (NASDAQ:FCEL)
Next post Roth Capital Issues Optimistic Forecast for CRC Earnings